Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a Parkinson's drug fix brain injury brain fog?

NCT ID NCT02260570

Symptom relief Sponsor: VA Office of Research and Development Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looked at whether the drug tolcapone can help veterans with mild traumatic brain injury improve memory and self-regulation. Fifty-five veterans underwent brain scans and cognitive tests while taking either tolcapone or a placebo. The goal was to see if the drug changes brain activity and boosts memory performance.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Tolcapone (Tasmar), a COMT inhibitor drug
What this could lead to
If it works, this could point toward a medication to help improve memory and impulse control after mild traumatic brain injury.
What could go wrong
This is a very early, small trial (55 people) testing brain scans and cognitive tests, not a proven treatment. Tolcapone may not show clear benefits and has known liver risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

55 people

The number who actually took part.

Started

Aug 2015

Finished

Jun 2021

Lead sponsor

A government agency

The lead sponsor is a US federal agency other than the NIH.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 50 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Veteran ages 18-50 and in general good health; * Able to read English at a 6th grade level; * Able to provide written informed consent; * Normal or corrected to normal visual acuity; * Stable doses of all medications (2 weeks or greater); * History of mild traumatic brain injury greater than 6 months prior to participation Exclusion Criteria: * Contraindications to magnetic resonance imaging (MRI) scanning; * Inability to complete basic fMRI requirements; * History of brain surgery or penetrating brain injury; * Uncontrolled blood pressure (low or high); * Contraindications to tolcapone use; * Use of medications or drugs with dopamine-related actions within 30 days; * Active substance abuse or dependence; * Clinically severe medical illness requiring treatment; * History of psychiatric hospitalization (past 1 year) or suicide attempt (past 5 years); * Seizures greater than 4 weeks after traumatic brain injury (TBI) event or seizures requiring active treatment; * History of brain tumor, stroke, Alzheimer's disease, aneurysm rupture, or multiple sclerosis; * History of schizophrenia, attention deficit hyperactivity disorder (ADHD) or psychiatric diagnosis EXCEPT depression or post-traumatic stress disorder (PTSD)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mild traumatic brain injury are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Brain Concussion post-traumatic stress disorder traumatic brain injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mild traumatic brain injury

Contacts and locations

Locations

  • VA Northern California Health Care System, Mather, CA

    Sacramento, California, 95655, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.